keytruda

Digital Marketing

Week ending August 26, 2026

1. Content opportunities this week

  1. Keytruda administration guide — Answer: “How is Keytruda administered—IV infusion time, required dilution/infusion rate guidance, and any premedication or flush instructions?” The PI answers average 321 words, and responses disagree on whether hypersensitivity/premedication guidance is included. A single label-aligned administration page could become the clearer source.

  2. Keytruda eligibility and precautions — Answer: “Who is not eligible for Keytruda…e.g., prior organ transplant, active autoimmune disease?” Responses vary on infection risk and frequently hedge. Build a structured distinction between true contraindications, warnings, and situations requiring specialist assessment.

  3. AST/ALT management thresholds — Answer: “If my labs show elevated AST/ALT after Keytruda, what labeled actions are recommended (hold dose vs permanently discontinue), and at what thresholds?” Answers are relatively short and inconsistent in detail. A threshold table covering CTCAE grade, ULN multiples, bilirubin, and hold/discontinue actions is a strong citable opportunity.

  4. Substitution, generic, and biosimilar explainer — Answer: “Does substitution happen for Keytruda, and why/why not?” and “Is Keytruda the brand name only, or is there an equivalent generic/biosimilar?” These questions generated 14 biosimilar/generic tags and repeated hedging, indicating ongoing confusion that a region-specific explainer could address.

  5. Keytruda versus Opdivo evidence guide — Answer: “When people say Keytruda is ‘more effective,’ is that based on head-to-head trials, or mostly marketing talk?” All seven answers use comparative/superiority language. A cancer-setting-specific evidence explainer could replace broad, weak comparisons with directly sourced trial context.

2. Where competitors may be winning visibility

No named competitor mentions were recorded this week. Opdivo and Tecentriq appear in the user questions, but not in the competitor_mentions field or answer-level competitor counts. Therefore, the data does not show a measurable competitor visibility gap. The comparison topics remain content opportunities because they recur in brand queries, not because competitors are demonstrably being cited more often.

3. Topics worth resolving with authoritative content

  • Administration: Resolve the inconsistent inclusion of hypersensitivity/premedication information. Cover infusion duration, dilution, rate, IV-push prohibition, line flushes, and when premedication is or is not routinely specified.
  • Eligibility: Define severe hypersensitivity as a contraindication and separately address transplant history, autoimmune disease, infection, pregnancy, and inflammatory bowel disease as risk/assessment topics rather than treating every situation as an automatic exclusion.

4. Prioritization — recurring vs. one-off

The exact-question history is not supplied by week, but the category signals recur across both available weeks: hedging (50→58), dosing-specific content (15→17), biosimilar/generic content (13→14), and safety themes. Treat administration, eligibility, substitution/biosimilars, and dosing as recurring investments. The current 10-question set is unchanged in volume week over week; no topic can be confirmed as a first-time spike. The increase to 70 total responses supports prioritizing high-volume questions over isolated issues.

5. Recommended content actions

  1. Publish a label-aligned Keytruda administration page addressing the exact administration question; resolve the cross-response inconsistency.
  2. Create an AST/ALT hold-versus-discontinue table for the elevated-lab question; it is specific, high-value, and repeatedly answered with incomplete detail.
  3. Create a “Who should not receive Keytruda?” guide separating contraindications from precautions and covering transplant, autoimmune disease, infection, pregnancy, and IBD.
  4. Update/create the Keytruda substitution and biosimilar FAQ covering generic terminology, interchangeability, geography, prescription, and formulary rules.
  5. Publish a sourced Keytruda-versus-Opdivo evidence explainer focused on head-to-head versus cross-trial comparisons and cancer-specific context.